1-3 of 3
Nandita Bose
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

Feven Tameire, Nicholas Collette, Sho Fujisawaa, Kathryn Bieging-Rolett, Crissy Dudgeon, Michael E. Stokes, Ben Harrison, Ashley LaCayo, Paulina Wojnarowicz, Jeremy Drees, Kirk A. Staschke, David Surguladze, Eric S. Lightcap, Nandita Bose
Journal: Blood
Blood (2023) 142 (Supplement 1): 2943.
https://doi.org/10.1182/blood-2023-181245
Published: 2023
Journal Articles

Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia

Nandita Bose, PhD, Clive S. Zent, MD, Betsy R. LaPlant, MS, Nadine Ottoson, Steven Leonardo, PhD, George J Weiner, MD, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2014) 124 (21): 5662.
https://doi.org/10.1182/blood.V124.21.5662.5662
Published: 2014
Journal Articles

Impaired I n Vitro Osteogenesis in Multiple Myeloma Bone Marrow Osteoprogenitor Cells.

Nandita Bose, PhD, Rachel A. Kahler, Xiaodong Li, Hope Bergemann, Vincent Rajkumar, PhD, Jennifer Westendorf, PhD, Masellis Anna, PhD
Journal: Blood
Blood (2004) 104 (11): 2349.
https://doi.org/10.1182/blood.V104.11.2349.2349
Published: 2004